RankingsPricing
  1. US-listed companies
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD
  3. Financials
  4. Diluted EPS

TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA

Market cap
$27.8B
P/E ratio
SummaryFinancials
Period EndDiluted EPS (USD)YoY (%)
Dec 31, 2024-1.4+190.00%
Dec 31, 2023-0.5-76.42%
Dec 31, 2022-2.1-657.89%
Dec 31, 20210.4-110.44%
Dec 31, 2020-3.6+300.00%
Dec 31, 2019-0.9-61.28%
Dec 31, 2018-2.3-85.55%
Dec 31, 2017-16.3-23328.57%
Dec 31, 20160.1-96.15%
Dec 31, 20151.8-48.88%
Dec 31, 20143.6+138.93%
Dec 31, 20131.5-33.78%
Dec 31, 20122.3-27.18%
Dec 31, 20113.1-15.80%
Dec 31, 20103.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)